Mevalonate Kinase Deficiency (Hyper-IgD Syndrome)
An inherited metabolic disorder of cholesterol biosynthesis that triggers recurrent, self-limited fever episodes and systemic inflammation, ranging from a moderate periodic fever syndrome to severe mevalonic aciduria.
- Periodic Fever Syndrome
- Biologic Therapy Access
- Specialist Genetic Review
- Typical Onset
- Infancy to Early Childhood
- Inheritance Pattern
- Autosomal Recessive
- Key Gene
- MVK
- Key Treatment Class
- IL-1 and IL-6 Pathway Biologics
Condition Overview
Mevalonate Kinase Deficiency (MKD) is an inherited autoinflammatory disorder caused by reduced activity of the mevalonate kinase enzyme, which is part of the cholesterol biosynthesis pathway. Reduced enzyme function leads to recurrent activation of the innate immune system and overproduction of inflammatory cytokines, particularly interleukin-1 beta.
The disorder spans a clinical spectrum. Its milder, more common form is historically called Hyperimmunoglobulinemia D Syndrome (HIDS), presenting with recurrent fever attacks usually beginning in infancy. A rare, severe form called mevalonic aciduria involves near-complete enzyme deficiency and is associated with developmental and growth abnormalities alongside the inflammatory features.
Episodes are typically self-limited but recurrent, often triggered by vaccination, minor infection, stress, or unclear factors, and can significantly affect quality of life and school or work attendance if not recognized and managed.
Types and Subtypes
MKD is classified along a clinical and biochemical severity spectrum reflecting how much residual mevalonate kinase enzyme activity remains.
Symptoms and Signs
MKD is characterized by recurrent episodes of fever and systemic inflammation, interspersed with symptom-free intervals.
Causes and Risk Factors
MKD is caused by inherited mutations in the MVK gene, which reduce the activity of the mevalonate kinase enzyme in the cholesterol biosynthesis pathway.
Diagnosis and Investigations
Diagnosis combines clinical pattern recognition with biochemical and genetic testing.
Disease Severity and Risk Stratification
MKD does not use a tumor-style staging system; severity is generally categorized by attack frequency, systemic impact, and biochemical severity.
Standard Treatment Options
Treatment aims to control inflammatory attacks and prevent long-term complications.
Advanced & Emerging Therapies
Biologic therapy targeting the interleukin-1 and interleukin-6 pathways has substantially changed management for patients with frequent or severe MKD attacks.
Targeted
IL-1 Receptor Antagonists / IL-1 Blockers
Used to reduce frequency and severity of inflammatory attacks in patients with moderate to severe disease.
Targeted
IL-6 Receptor Blockers
An alternative biologic approach for patients with inadequate response to IL-1-targeted therapy.
Precision Medicine
Genotype-Informed Treatment Planning
Treatment intensity is increasingly guided by residual enzyme activity and attack severity rather than a one-size-fits-all approach.
Biomarkers & Precision Medicine
Biochemical and genetic markers support diagnosis and help individualize treatment intensity.
When a Second Opinion May Be Important
Specialist autoinflammatory disease expertise can help refine both diagnosis and treatment escalation decisions.
Clinical Trials & Research
Prognosis & Outcome Factors
Most patients with MKD have a chronic but manageable disease course, with attack frequency often improving with age and effective biologic therapy reducing the inflammatory burden over time.
Supportive Care and Living with MKD
Supportive care focuses on managing attack symptoms, monitoring for complications, and supporting normal growth and development.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients and families with Mevalonate Kinase Deficiency obtain specialist rheumatology and genetics report review, coordinate second opinions on biologic therapy escalation, and connect with hospitals experienced in managing rare autoinflammatory disorders.
Get a free case reviewFrequently Asked Questions
MKD is an inherited autoinflammatory disorder caused by reduced activity of the mevalonate kinase enzyme, leading to recurrent fever attacks and systemic inflammation.
HIDS is the more common, moderate form of MKD, while mevalonic aciduria is a rare, severe form with near-complete enzyme deficiency and additional developmental features.
Vaccination, minor infections, physical exertion, and emotional stress are recognized triggers, though many attacks have no identifiable trigger.
Diagnosis combines a characteristic attack pattern with biochemical testing for mevalonic acid during an episode and genetic confirmation of MVK mutations.
Yes. Anti-inflammatory medications manage milder cases, while biologics targeting interleukin-1 or interleukin-6 pathways are used for more frequent or severe attacks.
Many patients experience a gradual decrease in attack frequency as they get older, though this varies between individuals.
Uncommonly, longstanding uncontrolled inflammation can lead to secondary amyloidosis affecting the kidneys, which is why regular monitoring is recommended.
MKD follows autosomal recessive inheritance, meaning both parents typically carry one copy of a mutated MVK gene.
Most children can be vaccinated on a schedule coordinated with their care team, who can plan for the possibility of a triggered fever episode.
Yes. CancerFax can help coordinate review of your rheumatology and genetic reports, facilitate second opinions on biologic therapy options, and connect you with specialist hospitals experienced in rare autoinflammatory disorders.
Exploring Care Options for Mevalonate Kinase Deficiency?
Send your medical reports for specialist review and connect with centers experienced in primary immunodeficiency and inherited metabolic-inflammatory disease management.